Fig. 8: Inhibiting bilateral tumor cell cycle leads to increased immune cells.

Vehicle or BEZ235, a dual PI3K/mTOR inhibitor, was administered to Vsx2-Cre+; Rb1lox/lox; p107−/−; Ptenlox/lox mice by oral gavage daily on post-natal days 2–6 and 22–26 and harvested at P30 for histological analysis. A IHC was used to detect Ki67 and CD45 positive cells. Dual PI3K/mTOR inhibition with BEZ235 inhibits tumor cell proliferation and increases CD45+ immune cells in the tumor. Results are representative of analysis of five mice from each group. B Ki67+ and CD45+ cells were counted from vehicle and BEZ235-treated retinae and graphed as the percent of positive cells (n = 5, each group). ***p < 0.001.